Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

by E-E Ke, Yi-Long Wu
Published 2016-06-01

Intratumoral genetic and immune microenvironmental heterogeneity in T4N0M0 (diameter ≥ 7 cm) non‐small cell lung cancers

by Jia−Tao Zhang, Song Dong, Li−Yan Ji, Jia−Ying Zhou, Zhi− Hong Chen, Jian Su, Qing−Ge Zhu, Meng−Min Wang, E−E. Ke, Hao Sun, Xue−Tao Li, Jin−Ji Yang, Qing Zhou, Xu− Chao Zhang, Xuan Gao, Xue−Ning Yang, Xuefeng Xia, Xin Yi, Wen−Zhao Zhong, Yi−Long Wu
Published 2022-05-01

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

by Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Published 2023-08-01